AlloMap: Changing Medical Practice and Revenue-Pierre Cassigneul-03/06/2012 - 8:30am

Event Information
Event Topic: 
AlloMap: Changing Medical Practice and Revenue
Event Date: 
03/06/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
Pierre Cassigneul
Event Speaker Title: 
CEO & President
Event Speaker Company: 
XDx
Event Speaker Bio: 

Pierre Cassigneul

Pierre Cassigneul is the president and chief executive officer for XDx. Mr. Cassigneul has more than 20 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States, including the global launch of several successful high-tech products. He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Mr. Cassigneul has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. Mr. Cassigneul holds a management degree from the Ecole Superieure de Commerce de Reims, France.

Event Details
Cost: 
$0
Event Details: 

Founded in 2000, XDx, Inc. is a privately held molecular diagnostics company that pioneered the application of gene expression profiling technology in the areas of transplant medicine and autoimmunity. XDx developed and commercializedthe first gene expression profiling test for heart transplant management, AlloMapĀ® Molecular Expression Testing.

AlloMap offers physicians a non-invasive tool to aid in the management of acute transplant rejection in heart transplant patients. AlloMap has been commercially available since 2005 and was cleared by the FDA in 2008 as a Class II Medical Device. The clinical use of AlloMap is part of the recommended guidelines for the care of heart transplant patients issued by the International Society of Heart and Lung Transplantation.

The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Payment Options Dec 12th Evening Event

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address